As the number of available treatments for psoriasis and atopic dermatitis grow, there is a need to find a way to identify which treatment will work best for each person. The goal of this study is to develop a test called a gene expression assay to see if the assay can predict treatment success and/or failure in participants with atopic dermatitis or psoriasis. 

This study aims to assess a mobile iPhone app called MAYA for use in middle-aged and older adults with anxiety or mood disorders.

Participants will be asked to use the app for at least two days a week, 20 minutes each day, for six weeks. Participants will have weekly check-ins as well as longer assessments at the beginning of the study, week 3, week 6 (end of treatment), and week 12 (follow up).

This observational biorepository study aims to determine the overlapping and distinct immunological changes in individuals over 60 years of age with HIV-Associated Neurocognitive Disorders (HAND).

To accomplish this goal, the study will evaluate virologically suppressed people living with HIV-1 and HAND. A control group of virologically suppressed people living with HIV with normal cognition will also be enrolled, as well as 50 HIV-1 negative individuals.

This clinical trial is for men and women who have relapsed or refractory acute myeloid leukemia (AML). 

The purpose of this study is to learn the maximal tolerated dose and/or the recommended dose of Ziftomenib (KO-539) in participants with relapsed or refractory AML.

Ziftomenib is an experimental drug that blocks the menin pathway in hopes of preventing or slowing the leukemia cells from growing and dividing. Investigational means that Ziftomenib has not yet been approved by the United States Food and Drug Administration (FDA).

This clinical trial is for men and women who have Epstein-Barr Virus- Associated Post-Transplant Lymphoproliferative Disorder (EBV-PTLD) following a solid organ transplant or Allogeneic Hematopoietic Cell Transplant (HCT) who did not respond well to treatment with rituximab or rituximab and chemotherapy.
   
The purpose of this study is to test how well tabelecleucel works for these groups of patients and to see what side effects may occur. 

The purpose of this study is to test the safety and tolerability of an experimental anticancer drug currently known as BGB-16673 for men and women who have B-cell malignancies.

Experimental means that it has not yet been approved by the US Food and Drug Administration (FDA).

BGB-16673 is an oral Bruton tyrosine kinase (BTK) targeted protein degrader, which targets and binds to BTK in the body, inhibiting its activity. BTK in the body allows malignant cells to survive and BTK inhibitors interfere with this process.

This clinical trial is for men and women with gastrointestinal (GI) or genitourinary (GU) cancers who have been diagnosed with a blood clot called a venous thromboembolism (VTE) which can include deep venous thrombosis (DVT) in the leg veins, and/or a pulmonary embolism (PE), which is a clot in the pulmonary artery in the lungs.
   

This clinical trial is for men and women who have Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia.
 
The purpose of this research is to gather information on the safety and effectiveness of PBCAR0191. PBCAR0191 is a new investigational treatment for certain types of blood cancers, such as leukemia and lymphoma, and is made from a type of blood cells known as T cells. 

This clinical trial is for men and women who have advanced hematologic malignancies (blood cancers) that may be treated with a blood stem cell transplant.
   
The purpose of this research study is to find out if an experimental therapy, Orca-T, can be safely given as a blood stem cell transplant to patients with blood cancers and pre-cancerous conditions and if Ora-T results in less graft vs host disease (GVHD) than standard blood stem cell transplants.
   

This study is being done to improve outcomes and treatment options in patients with chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL).

Patients will be treated with a combination of oral pills containing zanubrutinib and venetoclax. Depending on how each patient responds to treatment with the initial study drugs, a third drug called obinutuzumab may be added. Obinutuzumab is given by an intravenous (IV) infusion.